Suppr超能文献

COPD 中的炎症:对管理的影响。

Inflammation in COPD: implications for management.

机构信息

University at Buffalo, Buffalo, NY 14215, USA.

出版信息

Am J Med. 2012 Dec;125(12):1162-70. doi: 10.1016/j.amjmed.2012.06.024.

Abstract

Chronic obstructive pulmonary disease (COPD) is recognized by the Global Initiative for Chronic Obstructive Lung Disease guidelines as an inflammatory disease state, and treatment rationales are provided accordingly. However, not all physicians follow or are even aware of these guidelines. Research has shown that COPD inflammation involves multiple inflammatory cells and mediators and the underlying pathology differs from asthma inflammation. For these reasons, therapeutic agents that are effective in asthma patients may not be optimal in COPD patients. COPD exacerbations are intensified inflammatory events compared with stable COPD. The clinical and systemic consequences believed to result from the chronic inflammation observed in COPD suggest that inflammation intensity is a key factor in COPD and exacerbation severity and frequency. Although inhaled corticosteroids are commonly used and are essential in asthma management, their efficacy in COPD is limited, with only a modest effect at reducing exacerbations. The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents.

摘要

慢性阻塞性肺疾病(COPD)被全球慢性阻塞性肺疾病倡议指南确认为一种炎症性疾病状态,并据此提供治疗依据。然而,并非所有医生都遵循或甚至了解这些指南。研究表明,COPD 炎症涉及多种炎症细胞和介质,其潜在病理与哮喘炎症不同。基于这些原因,在哮喘患者中有效的治疗药物在 COPD 患者中可能不是最佳选择。与稳定期 COPD 相比,COPD 加重是炎症加剧的事件。据认为,COPD 中观察到的慢性炎症所导致的临床和全身后果表明,炎症强度是 COPD 以及加重严重程度和频率的关键因素。虽然吸入皮质类固醇在哮喘管理中被广泛使用且必不可少,但它们在 COPD 中的疗效有限,仅能适度减少加重。炎症在 COPD 中的重要性需要被临床医生更好地理解,并且应该仔细考虑 COPD 与哮喘之间的炎症差异,以优化抗炎药物的使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验